NANJING, China, May 21 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has applied for two Chinese patents for its flagship product, Cisatracurim besylate, a pre-surgical skeletal muscle relaxant.
The Company has applied to China's State Intellectual Property Office (SIPO) for a Chinese patent for Atracurium's freeze-drying compounds (Application Number 200710127756.2; "Atracurium's freeze-drying compounds"). This patent has already been published and is now awaiting certification.
The Company has also applied to SIPO for a Chinese patent for the preparation for separating and purifying Cisatracurim besylate through HPLC (Application Number 200910028198.3; "The preparation for separating and purifying Cisatracurim besylate through HPLC"). Using this method, the Company will reduce manufacturing costs and improve product quality.
Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
|SOURCE Sinobiopharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved